DYNAVAX TECHNOLOGIES CORP Contracts & Agreements

Rights Agreement, dated as of October 28, 2024 between Dynamix and Computershare Trust Company, N.A., which includes the form of Amended and Restated Certificate of Designation as... (Filed With SEC on October 29, 2024)

Dynavax Technologies Corporation 2018 Equity Incentive Plan (Filed With SEC on August 6, 2024)

Dynavax Technologies Corporation Annual Bonus Plan (Filed With SEC on August 6, 2024)

Sublease, dated March 7, 2024, by and between Company and Metagenomi, Inc (Filed With SEC on May 8, 2024)

Supply Agreement, effective as of September 7, 2023, by and between Company and Nitto Denko Avecia Inc (Filed With SEC on November 2, 2023)

Amendment No. 3 to Supply Agreement, dated effective as of April 26, 2023, by and between Company and Biological E. Limited (Filed With SEC on August 3, 2023)

Waiver and Second Amendment to Agreement, dated effective as of April 27, 2023, by and between Company and Coalition for Epidemic Preparedness Innovations (Filed With SEC on August 3, 2023)

Form of Management Continuity and Severance Agreement between Company and certain of its executive officers (Filed With SEC on August 3, 2023)

Amendment No. 1 to Supply Agreement, dated effective as of June 23, 2022, by and between the Company and Biological E. Limited (Filed With SEC on November 3, 2022)

Letter Agreement, dated August 30, 2022, by and among the Company, Zhejiang Clover Biopharmaceuticals, Inc., Clover Biopharmaceuticals (Hong Kong) Co., Limited and Sichuan Clover... (Filed With SEC on November 3, 2022)

Amendment No. 2 to Supply Agreement, dated effective as of September 30, 2022, by and between the Company and Biological E. Limited (Filed With SEC on November 3, 2022)

Letter Agreement No. 2, dated October 31, 2022, by and among the Company, Zhejiang Clover Biopharmaceuticals, Inc. and Clover Biopharmaceuticals (Hong Kong) Co., Limited (Filed With SEC on November 3, 2022)

Description of Capital Stock (Filed With SEC on February 28, 2022)

Restricted Stock Unit Award Agreement for Directors under the 2018 Equity Incentive Plan (Filed With SEC on February 28, 2022)

Letter Agreement, dated October 29, 2021, by and among the Company, Valneva Scotland Limited and Valneva Austria GmbH (Filed With SEC on February 28, 2022)

Non-Employee Director Compensation Policy (Filed With SEC on February 28, 2022)

Commercial Lease Agreement dated September 13, 2021 by and between Onyx Dsseldorf S. r.l. and Dynavax GmbH (Filed With SEC on November 4, 2021)

First Amendment to Commercial Manufacturing and Supply Agreement dated September 10, 2021 by and between Baxter Pharmaceutical Solutions LLC and Dynavax Technologies Corporation (Filed With SEC on November 4, 2021)

First Amendment to Agreement, dated May 3, 2021, between the Company and Coalition for Epidemic Preparedness Innovations (Filed With SEC on August 4, 2021)

Amendment No. 5 to Term Loan Agreement and Fee Letter, dated May 3, 2021, by and among Company, CRG Partners III L.P., CRG Partners III-Parallel Fund A L.P. and CRG Servicing LLC (Filed With SEC on August 4, 2021)

Amended and Restated Dynavax Technologies Corporation 2021 Inducement Award Plan (Filed With SEC on August 4, 2021)

Supply Agreement dated June 29, 2021 by and among Company, Zhejiang Clover Biopharmaceuticals, Inc., and Clover Biopharmaceuticals (Hong Kong) Co., Limited (Filed With SEC on August 4, 2021)

Supply Agreement dated July 1, 2021 by and between Company and Biological E. Limited (Filed With SEC on August 4, 2021)

Indenture, dated as of May 13, 2021, by and between Dynavax Technologies Corporation and U.S. Bank National Association, as Trustee (Filed With SEC on May 13, 2021)

Form of Confirmation for Capped Call Transactions (Filed With SEC on May 13, 2021)

Description of Capital Stock (Filed With SEC on February 25, 2021)

Agreement, dated January 29, 2021 between Company and Coalition for Epidemic Preparedness Innovations (Filed With SEC on February 25, 2021)

Amendment No. 4 to Term Loan Agreement and Fee Letter, dated January 29, 2021, by and among Company, CRG Partners III L.P., CRG Partners III-Parallel Fund A L.P. and CRG Servicing... (Filed With SEC on February 25, 2021)

Kelly MacDonald Employment Letter (Filed With SEC on February 25, 2021)

Dynavax Technologies Corporation 2021 Inducement Award Plan, Form of Stock Option Grant Notice, Option Agreement, Form of Restricted Stock Grant Notice and Restricted Stock Unit... (Filed With SEC on January 12, 2021)

Supply Agreement, dated September 11, 2020, by and among the Company, Valneva Scotland Limited and Valneva Austria GmbH (Filed With SEC on November 5, 2020)

Amended and Restated Management Continuity and Severance Agreement, dated September 22, 2020, between Michael S. Ostrach and the Company (Filed With SEC on November 5, 2020)

Amendment No. 3 to Term Loan Agreement and Fee Letter, dated November 2, 2020, by and among Company, CRG Partners III L.P., CRG Partners III-Parallel Fund A L.P. and CRG Servicing... (Filed With SEC on November 5, 2020)

Amended and Restated 2018 Equity Incentive Plan (Filed With SEC on August 6, 2020)

Amended and Restated 2004 Non-Employee Director Equity Program and Amended and Restated 2005 Non-Employee Director Cash Compensation Program, as amended (Filed With SEC on August 6, 2020)

Sales Agreement, dated August 6, 2020, between the Company and Cowen and Company, LLC (Filed With SEC on August 6, 2020)

Underwriting Agreement, dated May 21, 2020, by and among Dynavax Technologies Corporation, Cowen and Company, LLC, Evercore Group L.L.C. and William Blair & Company, L.L.C., as... (Filed With SEC on May 22, 2020)

Description of Capital Stock (Filed With SEC on March 11, 2020)

Chief Executive Officer Letter, dated December 13, 2019, between the Company and Ryan Spencer (Filed With SEC on March 11, 2020)

President and Chief Operating Officer Letter, dated December 13, 2019, between the Company and David Novak (Filed With SEC on March 11, 2020)

Dynavax Technologies Corporation U.S. Annual Bonus Plan (Filed With SEC on March 11, 2020)

Form of Indemnification Agreement (Filed With SEC on November 7, 2019)

Sublease, by and between Dynavax Technologies Corporation and MedAmerica, Inc. (d/b/a Vituity), dated July 2, 2019 (Filed With SEC on November 7, 2019)

Amendment No. 2 to Term Loan Agreement and Fee Letter, by and among Dynavax Technologies Corporation, CRG Partners III L.P., CRG Partners IIIParallel Fund A L.P. and CRG Servicing... (Filed With SEC on November 7, 2019)

Form of Series B Preferred Stock Certificate (Filed With SEC on November 7, 2019)

Sublease, by and between Dynavax Technologies Corporation and Zymergen Inc., dated July 12, 2019 (Filed With SEC on November 7, 2019)

Underwriting Agreement, dated April 7, 2019, by and among Dynavax Technologies Corporation, Cowen and Company, LLC and William Blair & Company, L.L.C., as representatives of the... (Filed With SEC on August 8, 2019)

Form of Warrant to Purchase Common Stock (Filed With SEC on August 8, 2019)

Amended and Restated 2018 Equity Incentive Plan (Filed With SEC on August 7, 2019)

Form of Amended and Restated Management Continuity and Severance Agreement between the Company and certain of its executive officers (Filed With SEC on August 7, 2019)

Co-President Officer Letter, dated May 30, 2019, between the Company and David Novack (Filed With SEC on August 7, 2019)

Co-President Officer Letter, dated May 30, 2019, between the Company and Ryan Spencer (Filed With SEC on August 7, 2019)

Office/Laboratory Lease, dated September 17, 2018, between the Company and Emery Station West, LLC (Filed With SEC on November 6, 2018)

2018 Equity Incentive Plan (Filed With SEC on June 1, 2018)

Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2018 Equity Incentive Plan (Filed With SEC on June 1, 2018)

Form of Option Grant Notice and Option Agreement under the 2018 Equity Incentive Plan (Filed With SEC on June 1, 2018)

Dynavax Technologies Corporation Amended And Restated 2004 Non-Employee Director Equity Program And Amended And Restated 2005 Non-Employee Director Cash Compensation Program (Filed With SEC on May 9, 2018)

Sublicense Agreement, effective as of February 16, 2018, by and between the Company and Merck, Sharp & Dohme Corp (Filed With SEC on May 9, 2018)

Master Services Agreement, dated January 11, 2016, between the Company and inVentiv Commercial Services, LLC (Filed With SEC on March 8, 2018)

Project Agreement, dated October 31, 2017 between the Company and inVentiv Commercial Services, LLC (Filed With SEC on March 8, 2018)

First Amendment to Project Agreement, dated October 31, 2017 between Company and inVentiv Commercial Services, LLC (Filed With SEC on March 8, 2018)

Commercial Manufacturing and Supply Agreement, dated November 22, 2013, between Company and Baxter Pharmaceutical Solutions LLC (Filed With SEC on March 8, 2018)

Supply Agreement, dated November 2, 2016, between Company and Becton, Dickinson and Company (Filed With SEC on March 8, 2018)

Supply Agreement, dated October 1, 2012, between Company and Nitto Denko Avecia, Inc (Filed With SEC on March 8, 2018)

Supply Agreement, dated July 27, 2016, between Company and West Pharmaceutical Services, Inc (Filed With SEC on March 8, 2018)

Dynavax Technologies Inducement Award Plan, Form of Stock Option Grant Notice, Option Agreement and Notice of Exercise, and Form of Restricted Stock Unit Award Grant Notice and... (Filed With SEC on November 30, 2017)

Sales Agreement, dated November 3, 2017, by and between the Company and Cowen and Company, LLC (Filed With SEC on November 3, 2017)

License Agreement, dated June 26, 2007, between Coley Pharmaceuticals Group, Inc. and the Company (Filed With SEC on November 3, 2017)

5,000,000 Shares DYNAVAX TECHNOLOGIES CORPORATION Common Stock UNDERWRITING AGREEMENT (Filed With SEC on August 10, 2017)

Fifth Amendment to Lease, dated as of May 24, 2017, between the Company and 2929 Seventh Street, LLC (Filed With SEC on August 7, 2017)

DYNAVAX TECHNOLOGIES CORPORATION Amended and Restated MANAGEMENT CONTINUITY AND SEVERANCE AGREEMENT (Filed With SEC on April 19, 2016)

AMENDMENT No. 7 (Filed With SEC on March 8, 2016)

DYNAVAX TECHNOLOGIES CORPORATION Common Stock (par value $0.001 per share) SALES AGREEMENT (Filed With SEC on November 12, 2015)

4,545,455 DYNAVAXTECHNOLOGIES CORPORATION Common Stock UNDERWRITING AGREEMENT (Filed With SEC on July 22, 2015)

DYNAVAX TECHNOLOGIES CORPORATION AMENDED AND RESTATED 2004 NON-EMPLOYEE DIRECTOR OPTION PROGRAM AND AMENDED AND RESTATED 2005 NON-EMPLOYEE DIRECTOR CASH COMPENSATION PROGRAM... (Filed With SEC on March 5, 2015)

AMENDMENT No. 6 (Filed With SEC on March 5, 2015)

LOAN AND SECURITY AGREEMENT (Filed With SEC on March 5, 2015)

SEE REVERSE SIDE FOR RESTRICTIVE LEGEND(S) (Filed With SEC on November 1, 2013)

79,570,000 Shares DYNAVAX TECHNOLOGIES CORPORATION Common Stock UNDERWRITING AGREEMENT (Filed With SEC on October 28, 2013)

43,430 Shares DYNAVAXTECHNOLOGIES CORPORATION Series B Convertible Preferred Stock UNDERWRITING AGREEMENT (Filed With SEC on October 28, 2013)

DYNAVAX TECHNOLOGIES CORPORATION (Filed With SEC on May 3, 2013)

DYNAVAX TECHNOLOGIES CORPORATION MANAGEMENT CONTINUITY AND SEVERANCE AGREEMENT (Filed With SEC on May 3, 2013)

CONSULTING AGREEMENT (Filed With SEC on May 3, 2013)

CONSULTING AGREEMENT (Filed With SEC on April 4, 2013)

DYNAVAX TECHNOLOGIES CORPORATION Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement (Filed With SEC on March 29, 2013)

FOURTH AMENDMENT TO LEASE (Filed With SEC on March 8, 2013)

LEASE BETWEEN 2929 SEVENTH STREET, L.L.C. (LANDLORD) AND DYNAVAX TECHNOLOGIES CORPORATION (TENANT) 2919 Seventh Street Berkeley, California (Filed With SEC on March 8, 2013)

DYNAVAX TECHNOLOGIES CORPORATION AMENDED AND RESTATED MANAGEMENT CONTINUITY AND SEVERANCE AGREEMENT (Filed With SEC on March 8, 2013)

CONSULTING AGREEMENT (Filed With SEC on November 2, 2012)

DYNAVAX TECHNOLOGIES CORPORATION AMENDED AND RESTATED 2004 NON-EMPLOYEE DIRECTOR OPTION PROGRAM AND AMENDED AND RESTATED 2005 NON-EMPLOYEE DIRECTOR CASH COMPENSATION PROGRAM... (Filed With SEC on August 3, 2012)

17,500,000 Shares DYNAVAX TECHNOLOGIES CORPORATION Common Stock UNDERWRITING AGREEMENT (Filed With SEC on May 10, 2012)

AMENDMENT No. 4 (Filed With SEC on March 12, 2012)

24,000,000 Shares DYNAVAX TECHNOLOGIES CORPORATION Common Stock UNDERWRITING AGREEMENT (Filed With SEC on November 8, 2011)

RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between ASTRAZENECA AB and DYNAVAX TECHNOLOGIES CORPORATION DATE: 1 September 2006 (Filed With SEC on October 31, 2011)

THIRD AMENDMENT TO LEASE (Filed With SEC on August 3, 2011)

DYNAVAX TECHNOLOGIES CORPORATION AMENDED AND RESTATED 2004 NON-EMPLOYEEDIRECTOR OPTION PROGRAM AND AMENDED AND RESTATED 2005 NON-EMPLOYEE DIRECTOR CASH COMPENSATION PROGRAM... (Filed With SEC on August 3, 2011)

DYNAVAX TECHNOLOGIES CORPORATION EQUITY DISTRIBUTION AGREEMENT (Filed With SEC on August 17, 2009)

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKEDBY BRACKETS, HAS BEEN OMITTEDAND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANTTO... (Filed With SEC on August 6, 2009)

DYNAVAX TECHNOLOGIES CORPORATION MANAGEMENT CONTINUITY AND SEVERANCE AGREEMENT (Filed With SEC on June 5, 2009)

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKEDBY BRACKETS, HAS BEEN OMITTED ANDFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO... (Filed With SEC on April 30, 2009)

DYNAVAX TECHNOLOGIES CORPORATION RESTRICTED STOCK UNIT GRANT NOTICE (2004STOCK INCENTIVE PLAN) (Filed With SEC on March 6, 2009)

DYNAVAX TECHNOLOGIES CORPORATION MANAGEMENT CONTINUITY AND SEVERANCE AGREEMENT Amended October 3, 2008 (Filed With SEC on March 6, 2009)

BETWEEN GLAXO GROUP LIMITED AND DYNAVAX TECHNOLOGIES CORPORATION RESEARCH AND DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on March 6, 2009)

between: DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation; and MELLON INVESTOR SERVICES LLC, a New Jersey limited liability company, as Rights Agent (Filed With SEC on November 6, 2008)

FORM OF RIGHT CERTIFICATE (Filed With SEC on November 6, 2008)

AMENDMENT NO. 1 TO COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on May 2, 2008)

ISS work by changing or reprogramming the immune responses that cause disease rather than just treating the symptoms of disease (Filed With SEC on March 17, 2008)

Current assets (Filed With SEC on November 6, 2007)

COLEY PHARMACEUTICAL GROUP, INC. (Filed With SEC on August 3, 2007)

Current assets (Filed With SEC on November 3, 2006)

Exhibit No (Filed With SEC on October 4, 2006)

Current assets (Filed With SEC on August 4, 2006)

Current assets (Filed With SEC on May 5, 2006)

5,000,000 Shares of Common Stock DYNAVAX TECHNOLOGIES CORPORATION UNDERWRITING AGREEMENT October 10, 2005 (Filed With SEC on October 12, 2005)

DYNAVAX TECHNOLOGIES CORPORATION 2004 NON-EMPLOYEE DIRECTOR OPTION PROGRAM (REVISED) AND 2005 NON-EMPLOYEE DIRECTOR CASH COMPENSATION PROGRAM EFFECTIVE APRIL 14, 2005 (REVISION... (Filed With SEC on April 18, 2005)

AIC for Ragweed Allergy. We have developed a novel injectable product candidate to treat ragweed allergy that we call AIC. AIC is an immunotherapeutic intervention for ragweed... (Filed With SEC on March 18, 2005)

Management Continuity and Severance Agreement, dated as of January 4, 2005, between the Registrant and Deborah A. Smeltzer (Filed With SEC on January 5, 2005)

DYNAVAX TECHNOLOGIES CORPORATION MANAGEMENT CONTINUITY AND SEVERANCE AGREEMENT (Filed With SEC on August 27, 2004)

DYNAVAX TECHNOLOGIES CORPORATION (Filed With SEC on February 11, 2004)

DYNAVAX TECHNOLOGIES CORPORATION (Filed With SEC on December 1, 2003)

Category

Industry

Companies

Contracts

DYNAVAX TECHNOLOGIES CORP Contracts & Agreements